UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 37

Sortiert nach

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Liver international, 2015-09, Vol.35 (9), p.2155-2166

2015

Volltextzugriff (PDF)

Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative

Pharmacoepidemiology and drug safety, 2020-11, Vol.29 (11), p.1504-1513

2020

Volltextzugriff (PDF)

Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials

BMC medicine, 2021-12, Vol.19 (1), p.307-307, Article 307

2021

Volltextzugriff (PDF)

Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative

Value in health, 2020-09, Vol.23 (9), p.1128-1136

2020

Volltextzugriff (PDF)

Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma

BMC gastroenterology, 2011-05, Vol.11 (1), p.53-53, Article 53

2011

Volltextzugriff (PDF)

Observational study to characterize treatment-resistant depression in Germany, France and the United Kingdom: analysis of real-world data collected through a survey of healthcare professionals

Current medical research and opinion, 2022-12, Vol.38 (12), p.2219-2226

2022

Volltextzugriff (PDF)

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US

Current medical research and opinion, 2004-12, Vol.20 (12), p.1929-1936

2004

Volltextzugriff (PDF)

Contribution of Hypoglycemia to Medical Care Expenditures and Short-Term Disability in Employees With Diabetes

Journal of occupational and environmental medicine, 2005-05, Vol.47 (5), p.447-452

2005

Volltextzugriff (PDF)

Patterns of Initial Pharmacotherapy for Parkinson’s Disease in the United States

Journal of geriatric psychiatry and neurology, 2006-06, Vol.19 (2), p.91-97

2006

Volltextzugriff (PDF)

Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4033-4033

2012

Volltextzugriff (PDF)

Total Health Care Costs in Medicaid Patients Receiving NPH, Lente, or Insulin Glargine

Diabetes (New York, N.Y.), 2005-06, Vol.54, p.A144

2005

Volltextzugriff (PDF)

UTILIZATION, RE-TREATMENT RATES AND COSTS OF 7-DAY, 10-DAY, AND 14-DAY HELICOBACTER PYLORI (H. PYLORI) TREATMENT REGIMENS: INSIGHTS FROM A MEDICAID ANALYSIS

The American journal of gastroenterology, 2004-10, Vol.99, p.S231

2004

Volltextzugriff (PDF)

UTILIZATION, RE-TREATMENT RATES AND COSTS OF 7-DAY, 10-DAY, AND 14-DAY HELICOBACTER PYLORI (H. PYLORI) TREATMENT REGIMENS: DATA FROM U.S. PUBLIC AND PRIVATE PAYER CLAIMS DATABASES

The American journal of gastroenterology, 2004-10, Vol.99, p.S228

2004

Volltextzugriff (PDF)

Burden of illness in Parkinson's disease

Movement disorders, 2005-11, Vol.20 (11), p.1449-1454

2005

Volltextzugriff (PDF)

Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures

Osteoporosis international, 2005-04, Vol.16 (4), p.359-371

2005

Volltextzugriff (PDF)

HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force

Pharmacoepidemiology and drug safety, 2023-01, Vol.32 (1), p.44-55

2023

Volltextzugriff (PDF)

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

Journal of medical economics, 2016-06, Vol.19 (6), p.630-644

2016

Volltextzugriff (PDF)

The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care

Journal of clinical oncology, 2016-01, Vol.34 (3_suppl), p.78-78

2016

Volltextzugriff (PDF)

Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance

Clinical gastroenterology and hepatology, 2011-07, Vol.9 (7), p.617-623.e1

2011

Volltextzugriff (PDF)

Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use

Value in health, 2013-09, Vol.16 (6), p.S16-S19

2013

Volltextzugriff (PDF)

QOL-08PATIENT RELEVANT OUTCOMES IN RECURRENT GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW

Neuro-oncology (Charlottesville, Va.), 2015-11, Vol.17 (suppl 5), p.v189.3-v189

2015

Volltextzugriff (PDF)

Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9031-9031

2016

Volltextzugriff (PDF)

P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S247

2016

Volltextzugriff (PDF)

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

Journal of thoracic oncology, 2016-10, Vol.11 (10), p.S171-S171

2016

Volltextzugriff (PDF)

1 – 25 von 37

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(36)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(37)

Sprache

Englisch
(37)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative

Comparative effectiveness and safety of pharmaceuticals assessed in observational studies compared with randomized controlled trials

Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative

Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma

Observational study to characterize treatment-resistant depression in Germany, France and the United Kingdom: analysis of real-world data collected through a survey of healthcare professionals

The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US

Contribution of Hypoglycemia to Medical Care Expenditures and Short-Term Disability in Employees With Diabetes

Patterns of Initial Pharmacotherapy for Parkinson’s Disease in the United States

Observations of hepatocellular carcinoma (HCC) management patterns from the global HCC bridge study: First characterization of the full study population

Total Health Care Costs in Medicaid Patients Receiving NPH, Lente, or Insulin Glargine

UTILIZATION, RE-TREATMENT RATES AND COSTS OF 7-DAY, 10-DAY, AND 14-DAY HELICOBACTER PYLORI (H. PYLORI) TREATMENT REGIMENS: INSIGHTS FROM A MEDICAID ANALYSIS

UTILIZATION, RE-TREATMENT RATES AND COSTS OF 7-DAY, 10-DAY, AND 14-DAY HELICOBACTER PYLORI (H. PYLORI) TREATMENT REGIMENS: DATA FROM U.S. PUBLIC AND PRIVATE PAYER CLAIMS DATABASES

Burden of illness in Parkinson's disease

Health care utilization and expenditures in the United States: a study of osteoporosis-related fractures

HARmonized Protocol Template to Enhance Reproducibility of Hypothesis Evaluating Real-World Evidence Studies on Treatment Effects: A Good Practices Report of a Joint ISPE/ISPOR Task Force

HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task force

Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes

The Quality of Survival (QoS): A concept framework to assist communication and decision making about cancer care

Factors That Affect Risk for Hepatocellular Carcinoma and Effects of Surveillance

Value-Based Assessment of Pharmacodiagnostic Testing from Early Stage Development to Real-World Use

QOL-08PATIENT RELEVANT OUTCOMES IN RECURRENT GLIOBLASTOMA: A SYSTEMATIC LITERATURE REVIEW

Lung Cancer Symptom Scale (LCSS) as a marker of treatment (tx) benefit with nivolumab (nivo) vs docetaxel (doc) in patients (pts) with advanced (adv) non-squamous (NSQ) NSCLC from CheckMate 057

P2.46 (also presented as PD1.01): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

PD1.01 (also presented as P2.46): LCSS as a Marker of Treatment Benefit With Nivolumab vs Docetaxel in Pts With Advanced Non-Squamous NSCLC From Checkmate 057

Suchergebnisse filtern